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Optically active imidazoles derived from enantiomerically
pure trans-1,2-diaminocyclohexane
Abstract
A new exploration of some monoprotected derivatives of trans-1,2-diaminocyclohexane as a
platform for the synthesis of enantiomerically pure imidazole derivatives is described. The
primary amino group (-NH2), present in the mono-imine derivative of salicylic aldehyde
(hemi-salen derivative) 5 was used for sequential reactions with formaldehyde and a
corresponding α-(hydroxyimino)ketone. (S)-(-)-1-Phenylethylamine was also used as starting
material for the preparation of new imidazole N-oxides 7c and 10a-c, bearing a chiral
N-(1-phenylethyl)carboxamido function at C(4). Imidazole N-oxides 10a-b possessing a Me or
i-Pr group at N(1), respectively, follow the known sulfur-transfer pathway affording the
corresponding imidazole-2-thiones 13a-b. However, in the case of imidazole N-oxide 10c with
the bulky adamantan-1-yl substituent at N(1), the attempted ‘sulfur-transfer reaction' led to
the deoxygenated imidazole derivative 14. Finally, the same reaction with 7c, bearing the
electron-withdrawing N-(1-phenylethyl)carboxamide residue at C(4) of the imidazole ring,
yielded a mixture of deoxygenated imidazole 16 and imidazole-2-thione 15c.
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Abstract— A new exploration of some monoprotected derivatives of trans-1,2-diaminocyclohexane as a platform for the 
synthesis of enantiomerically pure imidazole derivatives is described. The primary amino group (-NH2), present in the mono-
imine derivative of salicylic aldehyde (hemi-salen derivative) 5 was used for sequential reactions with formaldehyde and a 
corresponding α-(hydroxyimino)ketone. (S)-(–)-1-Phenylethylamine was also used as starting material for the preparation of 
new imidazole N-oxides 7c and 10a-c, bearing a chiral N-(1-phenylethyl)carboxamido function at C(4). Imidazole N-oxides 
10a-b possessing a Me or i-Pr group at N(1), respectively, follow the known sulfur-transfer pathway affording the 
corresponding imidazole-2-thiones 13a-b. However, in the case of imidazole N-oxide 10c with the bulky adamantan-1-yl 
substituent at N(1), the attempted ‘sulfur-transfer reaction’ led to the deoxygenated imidazole derivative 14. Finally, the same 
reaction with 7c, bearing the electron-withdrawing N-(1-phenylethyl)carboxamide residue at C(4) of the imidazole ring, 
yielded a mixture of deoxygenated imidazole 16 and imidazole-2-thione 15c. 
 
 
 
1. Introduction 
 Chiral 1,2-diamines are widely applied as easily 
available starting materials for the preparation of optically 
active heterocycles.2 Of special importance is trans-1,2-
diaminocyclohexane (1a), which can be isolated as pure 
enantiomers by resolution via diastereomeric tartrates.3 In 
recent papers we reported the efficient synthesis of bis-
imidazoles starting with enantiomerically pure 1a.4,5 The 
initially obtained N,N’-dioxides 2 were deoxygenated to 
give the bis-imidazoles 3, which subsequently were 
alkylated yielding the corresponding bis-imidazolium salts 
4.4b Some of the optically active N,N’-dioxides as well as 
the deoxygenated bis-imidazoles were successfully applied 
as organocatalysts for the asymmetric allylation of aromatic 
aldehydes5 and for asymmetric cyclopropanations.6 
Figure 1. trans-1,2-Diaminocyclohexane (1a) (DACH) as a substrate for 
preparation of C2-symmetrical bis-imidazole derivatives 24a, 34a and 44b. 
 The goal of the present study was the synthesis of new 
series of optically active imidazole N-oxides using some 
monoprotected derivatives of 1a. Furthermore, the 
primarily obtained N-oxides should be converted into the 
corresponding imidazole-2-thiones. Both, imidazole N-
oxides and imidazole-2-thiones are potentially attractive as 
new ligands for asymmetric synthesis or as organocatalysts. 
In numerous recent papers, some optically active 
azaaromatic N-oxides were demonstrated as efficient 
ligands.7a Moreover, it is well established that many 
thiourea derivatives, which can be considered as structural 
analogues of imidazole-2-thiones, act efficiently as 
organocatalysts and ligands for asymmetric synthesis.7b-e 
Nevertheless, to the best of our knowledge, no reports on 
the synthesis of optically active imidazole-2-thiones, 
potentially useful in asymmetric synthesis, are published to 
the date. H2N NH2
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2. Results and discussion 
 Several methods for the monoprotection of 1a are 
known, and the most frequently applied are N,N-
dialkylation,8 N-acetylation,9 and N-Boc-protection.10 In 
addition to these methods, the conversion to a monoimine 
with aldehydes or ketones is also described, and this type of 
monoprotection with salicylic aldehydes is of special 
importance (hemi-salen-type ligands).11 
 Based on a literature protocol, the desired monoimine 5 
was prepared in high yield and, without purification, it was 
reacted with paraformaldehyde (Scheme 1). The obtained 
crude product was used for the condensation with α-
hydroxyimino ketones 6 yielding, after heating for 8 h in 
ethanol, the desired imidazole 3-oxides 7 as crystalline 
materials. The enantiomeric purity of these products was 
proved by recording the 1H-NMR spectra with equimolar 
amounts of (S)-(–)-(tert-butyl)(phenyl)phosphinothioic acid 
(see Ref.4a). In both cases, there was only one set of the 
diagnostic signals for H-C(2) and HC=N. For example, in 
the spectrum of 7a, these signals appeared at 9.70 and 8.13 
ppm, respectively, and were significantly downfield shifted 
in comparison with the parent structure (7.82 and 8.00, 
respectively). 
Scheme 1. 
 Recently, we described an efficient method for the 
preparation of 3-oxidoimidazole-4-carboxamides using 2-
(hydroxyimino)-3-oxoamides in the reaction with N-
methylidene amines.12 For purposes of this study, (S)-(–)-
N-(1-phenylethyl)-2-hydroxyimino-3-oxobutyramide (8) 
was prepared by trapping of the in situ generated 
acetylketene13 with (S)-(–)-1-phenylethylamine (1b) and 
subsequent nitrosation of the β-oxoamide 9 (Scheme 2). In 
order to check the utility of 8 in the synthesis of 
enantiomerically pure 3-oxidoimidazole-4-carboxamides 
10, compound 8 was successfully employed in the reaction 
with N-methylidene amines 11 (R = Me, i-Pr, Ad). Even in 
the case of the bulky N-(adamant-1-yl)formaldimine (11c), 
the product 10c was obtained in fair yield. 
Scheme 2. 
 The successful synthesis of N-oxides 10 prompted us to 
use 8 for the reaction with 5 in order to prepare the more 
complex hemi-salen-like imidazole 3-oxide 7c, possessing 
three stereogenic centres (Scheme 3). 
Scheme 3. 
 As evidenced in a series of papers, 2-unsubstituted 
imidazole 3-oxides can be easily converted into the 
corresponding imidazole-2-thiones via sulfur-transfer 
reaction by treatment with 2,2,4,4-tetramethyl-3-
thioxocyclobutanone (12a) or the corresponding dithione 
12b.14 The reaction mechanism involves a [2+3] 
cycloaddition reaction as an initiating step. Both 
thioketones 12a and 12b are easily available and in contrast 
to other representatives of this class of sulfur-containing 
substances, can be stored for a longer time without 
decomposition.14a Earlier studies indicated, that they act as 
efficient dipolarophiles and superior ‘sulfur transferring 
agents’ in reactions with 2-unsubstituted imidazole 3-
oxides. With these 1,3-dipoles, they are more efficient than 
other popular thioketones, like thiobenzophenone or 
adamantanethione.14c According to the general ‘sulfur 
transfer’ protocol the new imidazole 3-oxides were treated 
with 12b in chloroform at room temperature. In the case of 
10a,b, the reactions occurred smoothly yielding, as 
expected, imidazole-2-thiones 13a,b as sole products 
(Scheme 4). However, in the case of 10c, bearing the bulky 
adamantyl substituent at N(1), the deoxygenated imidazole 
14 was obtained as the only product.15 A stepwise 
mechanism of the [2+3]-cycloaddition reaction leading to 
deoxygenation of starting imidazole N-oxide, reacting as a 
‘nitron-like’ 1,3-dipole, was extensively discussed in our 
earlier paper15 and an elusive oxathiirane, derived from 
12b, was evidenced as an intermediate. In order to confirm 
the structure of the isolated product, imidazole 3-oxide 10c 
was reacted with freshly prepared Raney-nickel and 
imidazole 14 was isolated as sole product in 61% yield. 
Scheme 4. 
 The reaction of dithione 12b with ‘hemi-salen derived’ 
imidazole 3-oxides 7a,b led to the expected imidazole-2-
thiones 15a,b in good yields (Scheme 5). The presence of 
the electron-withdrawing carboxamide group at C(4) in 7c 
slightly influenced the reaction course,15 and along with 
imidazole-2-thione 15c, the deoxygenated imidazole 16 
was formed. Both products were separated by column 
chromatography in 71% and 8% yield, respectively.  
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Scheme 5. 
 Surprisingly, in the 1H-NMR spectrum of 15c recorded 
in CDCl3, two sets of diagnostic signals (in ca. 4:1 ratio) 
were found. An analogous doubled-signal pattern was 
observed in CD3OD (ca. 3:1 ratio) as well as in DMSO-d6 
(ca. 5:3 ratio). The dynamic nature of 15c was proved by 
the registration of a series of 1H-NMR spectra in DMSO-d6 
at increased temperature (diagnostic part is shown in Figure 
2). A likely explanation of the observed phenomena is the 
formation of two rotamers (s-(Z)-15c and s-(E)-15c) 
stabilized by strong intramolecular hydrogen bonding of 
the amide function (Scheme 6). The IR spectrum of 15c 
supports this assumption; in contrast to the corresponding 
imidazole N-oxide 7c (νC=O 1660 cm-1) and the 
deoxygenated derivative 16 (νC=O 1653 cm-1), in the case of 
15c a significant shift of the amide C=O to 1629 cm-1 is 
observed. 
Scheme 6. 
 
Figure 2. The diagnostic part of 1H-NMR spectra (DMSO, 600 MHz) 
taken for 15c at variable temperatures. 
 In addition, the synthesis of imidazole derivatives of 1, 
analogous to 7, was attempted starting with mono-Boc and 
mono-acetyl protected trans-1,2-diaminocyclohexane (1a) 
and the α-(hydroxyimino)ketone 6a. In both cases, none of 
the expected imidazole N-oxides was obtained. 
3. Conclusions 
 The results presented in this paper show that the mono-
imine 5, derived from trans-1,2-diaminocyclohexane and 
salicylaldehyde, is a suitable substrate for the preparation of 
non-symmetrical, enantiomerically pure imidazole N-
oxides 7. On the other hand, optically active imidazole N-
oxides with a carboxamide function at C(4) can be prepared 
using 2-hydroxyimino-3-oxobutyramide 8, easily 
accessible from (S)(–)-1-phenylethylamine (1b) and in situ 
generated acetylketene. Examples of both classes of N-
oxides can be converted into the corresponding imidazole-
2-thiones 13 and 15. However, in the cases of 10c and 7c, 
bearing an electron-withdrawing carboxamido group at 
C(4) and a bulky substituent at N(1), the deoxygenation of 
the imidazole N-oxide was observed. The described 
enantiomerically pure imidazole derivatives are potentially 
attractive ligands for asymmetric syntheses. 
4. Experimental 
4.1. General 
 Melting points were determined in a capillary using a 
MEL-TEMP II apparatus (Aldrich) and are uncorrected. IR 
Spectra were recorded with a NEXUS FT-IR instrument as 
KBr pellets or as films; absorptions (ν) are given in cm–1. 
1H NMR and 13C NMR Spectra were recorded on a 
BRUKER AVANCE III (1H at 600 and 13C at 150 MHz) 
instrument in CDCl3, CD3OD or DMSO-d6 solutions; 
chemical shifts (δ) in ppm; coupling constants (J) in Hz. 
The multiplicity of the 13C signals was deduced from 
DEPT, supported by 1H-13C HMQC spectra. Optical 
rotations were determined on a PERKIN-ELMER 241 MC 
polarimeter. ESI mass spectra were measured on a Finnigan 
MAT-95 instrument. 
4.2. Starting materials 
 Applied reagents such as racemic trans-1,2-
diaminocyclohexane (technical grade), L-(+)-tartaric acid, 
salicylaldehyde, (S)-(–)-1-phenylethylamine, acetylacetone, 
2,2,6-trimethyl-4H-1,3-dioxin-4-one, other ketones, alkyl 
amines, paraformaldehyde, and solvents are commercially 
available and were used as received. Enantiomerically pure 
(R,R)-trans-1,2-diamino-cyclohexane was prepared by the 
resolution of racemic DACH using natural tartaric acid.3 
Formaldimines derived from methylamine, isopropylamine, 
and 1-adamantaneamine were prepared according to 
literature protocols.16 α-(Hydroxyimino)ketones were 
obtained according to known procedures: Butane-2,3-dione 
monooxime by nitrosation of butanone using isoamyl 
nitrite;17a 1,2-diphenylethane-1,2-dione monooxime (benzil 
monooxime) from dibenzoyl and hydroxylamine.17b 
Monoimine 518 was obtained in 90% yield (95% purity) and 
used in the next step without further purification. 
4.3. Synthesis of imidazole 3-oxides 7a-c 
 To the magnetically stirred solution of monoimine 5 
(10.0 mmol, 2.2 g) in dry ethanol (30 mL), containing 
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freshly activated molecular sieves 4Å, paraformaldehyde 
(11.0 mmol, 0.33 g) was added in one portion at 0 °C. The 
resulting mixture was allowed to reach r.t. and stirred 
overnight. Next, the respective α-(hydroxyimino)ketone 
(11.0 mmol; 1.11 g of 6a, 2.48 g of 6b, or 2.57 g of 8) was 
added and the mixture refluxed for 8 h. After the solution 
was cooled and filtered, the solvent was removed in vacuo, 
the oily residue was purified by column chromatography 
(CC) to give the product of type 7 as yellow solid. 
4.3.1. Imidazole 3-oxide 7a 
 Yield after CC (SiO2, AcOEt then AcOEt/MeOH 1:1, Rf 
= 0.36): 1.60 g (51%). Yellow solid. Mp 139–141 °C. IR 
(KBr): 3420vs (br.), 2935s, 2860m, 1629vs, 1579m, 
1497m, 1452m, 1413m, 1339m, 1275m, 1208m, 1197m, 
759m. 1H NMR (CDCl3): 12.70 (s, 1H, OH); 8.00 (s, 1H, –
N=CH–); 7.82 (s, 1H, HC(2)); 7.32-7.29 (m, 1 arom. H); 
7.14 (dd, J = 7.8, J = 1.8, 1 arom. H); 6.90 (dd, J = 8.4, J = 
1.2, 1 arom. H); 6.86 (dt, J = 7.8, J = 1.2, 1 arom. H); 4.03-
3.99 (m, 1H, cHex); 3.23-3.19 (m, 1H, cHex); 2.19-2.12 
(m, 2H, cHex); 2.07, 2.03 (2s, 6H, 2Me); 2.01-1.47 (m, 6H, 
cHex). 13C NMR (CDCl3): 165.7 (s, –N=CH–); 160.5 (s, 
(Ph)C-OH); 132.8, 132.0, 119.0, 116.7 (4d, 4CH(Ph)); 
125.8, 121.8, 118.2 (3s, C(Ph), C(4), C(5)); 121.4 (d, C(2)); 
73.9, 59.3 (2d, CH(cHex)); 34.1, 32.4, 25.1, 23.8 (4t, 
4CH2(cHex)); 8.9, 7.0 (2q, 2Me). ESI-HRMS: 314.1862 
(calcd. 314.1863 for C18H24N3O2, [M+1]+). [α]D25 = –387.3 
(c 1.10, CHCl3), [α]D25 = –386.9 (c 0.50, CHCl3), [α]D25 = –
388.0 (c 0.25, CHCl3). 
4.3.2. Imidazole 3-oxide 7b 
 Yield after CC (SiO2, AcOEt then AcOEt/MeOH 1:1, Rf 
= 0.74): 1.88 mg (43%). Yellow solid. Mp 117–120 °C. IR 
(KBr): 3420vs (br.), 3060m, 2934s, 2858m, 1671m, 
1628vs, 1578m, 1497m, 1446m, 1406m, 1340m, 1279m, 
765m, 712m. 1H NMR (CDCl3): 12.33 (s, 1H, OH); 8.22 (s, 
1H, HC(2)); 8.21 (s, 1H, –N=CH–); 7.45-7.36 (m, 5 arom. 
H); 7.31-7.28 (m, 1 arom. H); 7.23 (dd, J = 7.2, J = 1.2, 1 
arom. H); 7.19-7.16 (m, 3 arom. H); 7.11-7.09 (m, 2 arom. 
H); 6.93-6.89 (m, 1 arom. H); 6.86 (dt, J = 7.5, J = 1.2, 1 
arom. H); 4.03-3.98 (m, 1H, cHex); 3.40-3.36 (m, 1H, 
cHex); 2.20-2.16 (m, 1H, cHex); 1.96-1.74 (m, 4H, cHex); 
1.63-1.56 (m, 1H, cHex); 1.49-1.41 (m, 1H, cHex); 1.37-
1.30 (m, 1H, cHex). 13C NMR (CDCl3): 165.7 (s, –N=CH–
); 160.5 (s, (Ph)C-OH); 132.8, 132.0, 130.9 (2C), 129.6, 
129.5 (2C), 129.1 (2C), 128.0, 127.9 (2C), 119.0, 116.7 
(10d, 14CH(Ph)); 128.1, 127.1, 126.5, 125.6, 118.3 (5s, 
3C(Ph), C(4), C(5)); 123.2 (d, C(2)); 72.9, 59.9 (2d, 
CH(cHex)); 34.0, 33.3, 24.9, 23.6 (4t, 4CH2(cHex)). ESI-
HRMS: 438.2174 (calcd. 438.2176 for C28H28N3O2, 
[M+1]+). [α]D25 = –81.0 (c 1.05, CHCl3). 
4.3.3. Imidazole 3-oxide 7c 
 Yield after CC (SiO2, AcOEt then AcOEt/MeOH 6:1, Rf 
= 0.54): 2.05 g (46%). Yellow solid. Mp 99–102 °C. IR 
(KBr): 3427s (br.), 2935s (br.), 2862m, 1660s, 1629s, 
1598s, 1546s (br.), 1495m, 1449m, 1416m, 1279s, 758m, 
700m. 1H NMR (CDCl3): 12.45 (s, 1H, OH); 11.00 (d, J = 
7.8, 1H, NH); 8.09 (s, 1H, –N=CH–); 7.97 (s, 1H, HC(2)); 
7.34-7.30 (m, 2 arom. H); 7.27-7.25 (m, 3 arom. H); 7.19-
7.17 (m, 1 arom. H); 7.10 (dd, J = 7.8, J = 1.8, 1 arom. H); 
6.89-6.85 (m, 1 arom. H); 6.80 (dt, J = 7.5, J = 1.2, 1 arom. 
H); 5.20 (quint, J = 7.1, 1H); 4.22-4.18 (m, 1H, cHex); 3.29 
(dt, J = 10.5, J = 4.3, 1H, cHex); 2.58 (s, 3H, Me); 2.12-
1.91 (m, 4H, cHex); 1.80-1.72 (m, 3H, cHex); 1.56-1.46 
(m, 1H, cHex); 1.52 (d, J = 7.1, 3H, Me). 13C NMR 
(CDCl3): 166.0 (s, –N=CH–); 160.6 (s, (Ph)C-OH); 158.6 
(s, CONH); 143.7, 131.3, 121.4, 118.0 (4s, 2C(Ph), C(4), 
C(5)); 133.1, 131.9, 128.5 (2C), 126.9, 126.0 (2C), 119.0, 
117.1 (7d, 9CH(Ph)); 122.5 (d, C(2)); 72.9, 59.4, 48.1 (3d, 
3CH); 34.4, 32.6, 25.0, 23.7 (4t, 4CH2(cHex)); 22.9, 9.7 
(2q, 2Me). ESI-HRMS: 447.2387 (calcd. 447.2391 for 
C26H31N4O3, [M+1]+). [α]D25 = –195.0 (c 1.00, CHCl3). 
4.4. Synthesis of (S)-(–)-N-(1-phenylethyl)-2-
hydroxyimino-3-oxobutyramide (8) 
A mixture of (S)-(–)-1-phenylethylamine (1b, 6.61 g, 54.6 
mmol) and 2,2,6-trimethyl-4H-1,3-dioxin-4-one (9.09 g, 
64.1 mmol) in dry toluene (150 mL) was refluxed for 16 h. 
After the solvent was removed under reduced pressure, the 
residue was flash chromatographed (SiO2, AcOEt/CHCl3 
1:2, Rf = 0.37) to give crude β-oxoamide 9 (10.82 g, 96 %) 
as pale orange oil, which was used in the next step without 
purification. The amide 9 (10.82 g, 52.8 mmol) was 
dissolved in glacial AcOH (25.0 mL), the resulting mixture 
was magnetically stirred while cooling (water/ice bath), and 
a solution of sodium nitrite (4.9 g, 71.0 mmol) in H2O (7.0 
mL) was added dropwise. After ca. 2.5 h, the mixture was 
diluted with H2O (90 mL) and extracted with three portions 
of CH2Cl2 (70 mL each). The combined organic phases 
were washed with a saturated aqueous solution of NaHCO3, 
then with water, dried with MgSO4, and the solvent 
removed. The crude product was flash chromatographed 
(SiO2, CH2Cl2) and purified by CC (SiO2, petroleum 
ether/Et2O 9:1, Rf = 0.25) to give 8 (6.52 g) as a pale yellow 
oil in 51 % overall yield. IR: 3281vs (br.), 2980s, 1686vs, 
1648vs, 1551vs, 1496m, 1451m, 1416m, 1363m, 1107m, 
1019m, 700m. 1H NMR (CDCl3): 9.39 (br. s, 1H, NH); 
7.38-7.35 (m, 2 arom. H); 7.32-7.28 (m, 3 arom. H); 5.15 
(quint, J = 7.2, 1H); 2.50 (s, 3H, Me); 1.57 (d, J = 7.2, Me). 
13C NMR (CDCl3): 199.6 (s, C=O); 162.6 (s, CONH); 
143.4 (s, C=N); 141.6 (s, C(Ph)); 128.9, 127.8, 126.0 (3d, 
5CH(Ph)); 48.7 (d, CH); 26.2, 21.9 (2q, 2 Me). ESI-HRMS: 
257.0894 (calcd. 257.0896 for C12H14N2NaO3, [M+Na]+). 
[α]D
22 = –98.3 (c 1.05, MeOH). 
4.5. Synthesis of imidazole 3-oxides 10a and 10b 
A solution of (S)-N-(1-phenylethyl)-2-hydroxyimino-3-
oxobutyramide (8, 2.34 g, 10.0 mmol) and the respective 
formaldimine 11 (12.0 mmol) in ethanol (30 mL) was 
refluxed for 5 h. After the solvent was removed, the residue 
was washed with Et2O (3 portions of ca. 20 mL) and 
purified by recrystallization (10a) or chromatography 
(10b). 
4.5.1. (S)-N-(Phenylethyl)-1,5-dimethyl-3-oxido-1H-
imidazole-4-carboxamide (10a) 
 Yield: 1.86 g (72%). Colorless solid. Mp 170–171 °C 
(CHCl3/Et2O). IR (KBr): 3442vs, 3152m, 1655vs, 1604s, 
1558m, 1448m, 1290m, 766m, 704m. 1H NMR (CDCl3): 
 5 
11.15 (br. d, J = 6.6, 1H, CONH); 7.74 (s, 1H, HC(2)); 
7.40-7.39 (m, 2 arom. H); 7.33-7.30 (m, 2 arom. H); 7.22-
7.20 (m, 1 arom. H); 5.27 (quint, J = 7.2, 1H); 3.55 (s, 3H, 
MeN); 2.59 (s, 3H, Me); 1.57 (d, J = 7.2, 3H, Me). 13C 
NMR (CDCl3): 158.6 (s, C=O); 143.8, 130.6, 125.2 (3s, 
C(Ph), C(4), C(5)); 128.3, 126.7, 125.8, 121.9 (4d, 
5CH(Ph), C(2)); 48.0 (d, CH); 31.7, 22.8, 9.2 (3q, 3 Me). 
ESI-HRMS: 282.1212 (calcd. 282.1213 for C14H17N3NaO2, 
[M+Na]+), 260.1392 (calcd. 260.1393 for C14H18N3O2, 
[M+1]+). [α]D25 = –12.5 (c 1.03, CHCl3). 
4.5.2. (S)-N-(Phenylethyl)-1-isopropyl-5-methyl-3-oxido-
1H-imidazole-4-carboxamide (10b) 
 Yield after CC (SiO2, AcOEt/MeOH 1:1, Rf = 0.51): 
2.36 g (82%). Colorless solid. Mp 124–126 °C. IR (KBr): 
3432s, 3100-2850s (br.), 1659vs, 1603s, 1551s, 1495m, 
1452m, 1284s, 705m, 700m. 1H NMR (CDCl3): 11.23 (br. 
s, 1H, CONH); 7.87 (s, 1H, HC(2)); 7.41-7.40 (m, 2 arom. 
H); 7.32-7.30 (m, 2 arom. H); 7.23-7.20 (m, 1 arom. H); 
5.27 (quint, J = 7.2, 1H); 4.40-4.33 (m, 1H, iPr); 2.63 (s, 
3H, Me); 1.57 (d, J = 7.2, 3H, Me); 1.45 (dd, J = 10.8, J = 
6.6, 6H, iPr). 13C NMR (CDCl3): 158.9 (s, C=O); 143.9, 
129.6, 121.8 (3s, C(Ph), C(4), C(5)); 128.4, 126.8, 126.0, 
122.3 (4d, 5CH(Ph), C(2)); 48.1, 47.8 (2d, 2CH); 22.9, 
22.7, 9.3 (3q, 4 Me). ESI-HRMS: 310.1527 (calcd. 
310.1526 for C16H21N3NaO2, [M+Na]+), 288.1706 (calcd. 
288.1706 for C16H22N3O2, [M+1]+). [α]D25 = –12.3 (c 10.0, 
CHCl3). 
4.6. Synthesis of (S)-N-(Phenylethyl)-1-adamantyl-5-
methyl-3-oxido-1H-imidazole-4-carboxamide (10c) 
The solution of 1-adamantaneformaldimine (11c, 1.96 g, 
12.0 mmol) and α-(hydroxyimino)ketone 8 (2.34 g, 10.0 
mmol) in glacial AcOH (30 mL) was stirred for 2 days at 
r.t. Then, a stream of dry HCl gas was bubbled through the 
mixture for 1.5 h, and the solvents were removed under 
reduced pressure. The resulting yellow oil was triturated 
with Et2O, decanted, dried under vacuum, and dissolved in 
a 4:1 mixture of CHCl3 and methanol. After excess solid 
NaHCO3 was added, vigorous stirring was continued for 2 
h. Then, the mixture was filtered, the solvents were 
removed, and the resulting solid was recrystallized from 
CH2Cl2/Et2O to give 1.81 g (48%) of 10c as colorless 
crystals. Mp 257–260 °C. IR (KBr): 3432vs (br.), 3135m, 
1916vs, 1663vs, 1589vs, 1551s, 1495m, 1452m, 1409m, 
1388m, 1374m, 1278s, 1212m, 1152m, 1103m, 763m, 
747m, 698m. 1H NMR (CDCl3): 11.24 (br. s, 1H, CONH); 
7.93 (s, 1H, HC(2)); 7.41-7.39 (m, 2 arom. H); 7.32-7.30 
(m, 2 arom. H); 7.23-7.20 (m, 1 arom. H); 5.25 (quint, J = 
7.2, 1H); 2.88 (s, 3H, Me); 2.28 (br. s, 3H, CH, Ad); 2.19 
(d, J = 2.4, 6H, CH2, Ad); 1.80-1.73 (m, 6H, CH2, Ad); 
1.56 (d, J = 7.2, 3H, Me). 13C NMR (CDCl3): 159.2 (s, 
C=O); 144.1, 130.8, 123.4 (3s, C(Ph), C(4), C(5)); 128.5, 
126.8, 126.1 (3d, 5CH(Ph)); 60.6 (s, N-C(Ad)); 48.3 (d, 
CH); 41.9, 29.6 (2t, 6CH2, Ad); 35.5 (d, 3CH, Ad); 23.0, 
13.2 (2q, 2Me). ESI-HRMS: 402.2152 (calcd. 402.2152 for 
C23H29N3NaO2, [M+Na]+), 380.2331 (calcd. 380.2332 for 
C23H30N3O2, [M+1]+). [α]D25 = –6.4 (c 5.00, CHCl3). 
4.7. Reactions of imidazole 3-oxides of type 7 and 10 
with 2,2,4,4-tetramethylcyclobutane-1,3-dithione (12b) 
 To the magnetically stirred solution of an imidazole N-
oxide 7a-c or 10a-c (1.0 mmol) in CHCl3 (5 mL), excess 
2,2,4,4-tetramethylcyclobutane-1,3-dithione (12b, 1.8 
mmol, 309 mg) in CHCl3 (3 mL) was added dropwise at 0 
°C, and stirring was continued overnight, at r.t.. Then, the 
solvent was removed under reduced pressure, the resulting 
material was purified and identified as the corresponding 
imidazole-2-thione (13 or 15) and/or as an imidazole (14 
and 16). 
4.7.1. (S)-N-(1-Phenylethyl)-1,3-dihydro-1,5-dimethyl-
2(3H)-thioxoimidazole-4-carboxamide (13a) 
 Yield: 98 mg (36%). Colorless crystals. Mp 221–223 
°C (EtOH). IR (KBr): 3312vs, 3166vs (br.), 1661s, 1626m, 
1537m, 1487m, 1475m, 1450m, 1425m, 1395m, 1368m, 
763m, 702m. 1H NMR (CDCl3): 12.83 (br. s, 1H, NH); 
7.48 (br. d, J = 7.8, 1H, NH); 7.30-7.28 (m, 2 arom. H); 
7.23-7.20 (m, 2 arom. H); 7.16-7.13 (m, 1 arom. H); 5.16 
(quint, J = 7.2, 1H); 3.41 (s, 3H, NMe); 2.42 (s, 3H, Me); 
1.51 (d, J = 6.6, 3H, Me). 13C NMR (CDCl3): 158.9, 157.5 
(2s, C=O, C=S); 143.2, 134.1, 118.7 (3s, C(Ph), C(4), 
C(5)); 128.5, 127.2, 126.4 (3d, 5CH(Ph)); 49.3 (d, CH); 
31.0, 22.1, 10.2 (3q, 3 Me). ESI-HRMS: 298.0986 (calcd. 
298.0984 for C14H28N3NaOS, [M+Na]+). [α]D25 = +326.3 (c 
0.80, CHCl3). 
4.7.2. (S)-N-(1-Phenylethyl)-1,3-dihydro-1-isopropyl-5-
methyl-2(3H)-thioxoimidazole-4-carboxamide (13b) 
 Yield after CC (SiO2, AcOEt/CHCl3 1:2, Rf = 0.65): 
173 mg (56%). Colorless solid. Mp 107–110 °C. IR (KBr): 
3304s (br.), 3061m, 2973m, 2933m, 1656m, 1626s, 1540m, 
1494s, 1451m, 1416m, 1370m, 1282m, 1197m, 763m, 
700m. 1H NMR (CDCl3): 13.11 (br. s, 1H, NH); 7.62 (br. d, 
J = 7.2, 1H, NH); 7.38-7.37 (m, 2 arom. H); 7.30-7.28 (m, 
2 arom. H); 7.23-7.20 (m, 1 arom. H); 5.30 (br. s, 1H, iPr); 
5.23 (quint, J = 7.2, 1H); 2.64 (s, 3H, Me); 1.57 (d, J = 7.2, 
3H, Me); 1.52-1.49  (m, 6H, iPr). 13C NMR (CDCl3): 158.0 
157.7 (2s, C=O, C=S); 143.4, 134.0, 119.3 (3s, C(Ph), C(4), 
C(5)); 128.5, 127.2, 126.3 (3d, 5CH(Ph)); 49.5, 49.2 (2d, 
2CH); 22.1, 20.4, 11.1 (3q, 4 Me). ESI-HRMS: 326.1299 
(calcd. 326.1297 for C16H21N3NaOS, [M+Na]+). [α]D25 = 
+149.0 (c 1.00, CHCl3). 
4.7.3. (S)-N-(Phenylethyl)-1-adamantyl-5-
methylimidazole-4-carboxamide (14) 
 Yield after CC (SiO2, AcOEt/CHCl3 1:2, Rf = 0.70): 203 
mg (56%). Colorless solid. Mp 132–134 °C. IR (KBr): 
3407m, 2910s, 2856m, 1660vs, 1578s, 1494vs, 1452m, 
1235m, 697m. 1H NMR (CDCl3): 7.59 (br. s, 1H, NH); 
7.51 (s, 1H, HC(2)); 7.40-7.38 (m, 2 arom. H); 7.33-7.29 
(m, 2 arom. H); 7.23-7.20 (m, 1 arom. H); 5.25 (quint, J = 
7.2, 1H); 2.86 (s, 3H, Me); 2.25 (br. s, 3H, 3CH, Ad); 2.21 
(d, J = 2.4, 6H, 3CH2, Ad); 1.80-1.74 (m, 6H, 3CH2, Ad); 
1.56 (d, J = 7.2, 3H, Me). 13C NMR (DMSO-d6): 162.9 (s, 
C=O); 145.1, 132.2, 131.5 (3s, C(Ph), C(4), C(5)); 133.6 
(d, C(2)); 128.4 (2C), 126.7, 126.2 (2C) (3d, 5CH(Ph)); 
57.9 (s, N-C(Ad)); 47.4 (d, CH); 41.5, 29.2 (2t, 6CH2, Ad); 
35.4 (d, 3CH, Ad); 22.4, 12.8 (2q, 2Me). ESI-HRMS: 
386.2200 (calcd. 386.2203 for C23H29N3NaO, [M+Na]+), 
 6 
364.2384 (calcd. 364.2383 for C23H30N3O, [M+1]+). [α]D25 
= –33.0 (c 1.00, CHCl3). 
4.7.4. Imidazole-2-thione 15a 
 Yield after CC (SiO2, AcOEt/CHCl3 1:1, Rf = 0.74): 
259 mg (79%). Yellow solid. Mp 89–92 °C. IR (KBr): 
3423s (br.), 3166m, 3069s, 2929vs, 2857s, 1629vs, 1497m, 
1450m, 1388m, 1370m, 1353m, 1278m, 756m. 1H NMR 
(CDCl3): 13.30 (s, 1H, OH); 10.30 (br. s, 1H, NH); 8.34 (s, 
1H, –N=CH–); 7.18-7.15 (m, 1 arom. H); 7.12 (d, J = 7.2, 1 
arom. H); 6.81 (d, J = 8.4, 1 arom. H); 6.75 (t, J = 7.2, 1 
arom. H); 5.19-5.16 (m, 1H, cHex); 3.86-3.81 (m, 1H, 
cHex); 3.31-3.24 (m, 1H, cHex); 1.91, 1.85 (2s, 6H, 2Me); 
1.76-1.51 (m, 6H, cHex); 1.36-1.28 (m, 1H, cHex). 13C 
NMR (CDCl3): 165.7 (s, –N=CH–); 161.1 (s, (Ph)C-OH); 
157.2 (s, C=S); 132.1, 131.7, 118.5, 116.7 (4d, 4CH(Ph)); 
122.8, 119.4, 118.8 (3s, C(Ph), C(4), C(5)); 64.9, 61.6 (2d, 
2CH(cHex)); 34.5, 27.2, 25.6, 23.7 (4t, 4CH2(cHex)); 9.2, 
9.0 (2q, 2Me). ESI-HRMS: 330.1632 (calcd. 330.1635 for 
C18H24N3OS, [M+1]+). [α]D25 = –294.0 (c 1.00, CHCl3). 
4.7.5. Imidazole-2-thione 15b 
 Yield after CC (SiO2, AcOEt/CHCl3 1:8, Rf = 0.54): 
285 mg (63%). Yellow solid. Mp 278–281 °C. IR (KBr): 
3427vs (br.), 3058vs (br.), 2936vs, 2853m, 1627s, 1579m, 
1495s, 1446m, 1384m, 1355m, 1274m, 1261m, 1237m, 
754m, 695m. 1H NMR (CDCl3): 13.08 (s, 1H, OH); 9.86 
(br. s, 1H, NH); 8.56 (s, 1H, –N=CH–); 7.53-7.50 (m, 3 
arom. H); 7.27-7.24 (m, 3 arom. H); 7.20 (d, J = 7.8, 1 
arom. H); 7.16-7.15 (m, 3 arom. H); 7.03-6.99 (m, 2 arom. 
H); 6.91 (d, J = 8.4, 1 arom. H); 6.18 (t, J = 7.5, 1 arom. 
H); 5.47-5.43 (m, 1H, cHex); 3.79-3.75 (m, 1H, cHex); 
3.23-3.17 (m, 1H, cHex); 1.87-1.63 (m, 4H, cHex); 1.54-
1.38 (m, 2H, cHex); 1.28-1.25 (m, 1H, cHex). 13C NMR 
(CDCl3): 166.0 (s, –N=CH–); 161.0 (s, (Ph)C-OH); 159.7 
(s, C=S); 137.0, 133.7, 124.6, 119.8, 118.8 (5s, 3C(Ph), 
C(4), C(5)); 132.2, 131.8, 129.8, 129.4, 129.3, 128.7 (2C), 
128.1, 128.0, 127.7, 125.9 (2C), 118.6, 116.8 (12d, 
14CH(Ph)); 64.8, 62.1 (2d, CH(cHex)); 34.4, 27.7, 25.3, 
23.7 (4t, 4CH2(cHex)). ESI-HRMS: 454.1949 (calcd. 
454.1948 for C28H28N3OS, [M+1]+). [α]D25 = –69.0 (c 1.00, 
CHCl3). 
4.7.6. Imidazole-2-thione 15c 
 Yield after CC (SiO2, AcOEt/CHCl3 1:1, isolated as less 
polar fraction, Rf = 0.79): 328 mg (71%). Pale yellow solid. 
Mp 138–140 °C. IR (KBr): 3432vs (br.), 2931s, 1629vs 
(br.), 1533m, 1494s, 1452m, 1384m, 1348m, 1278s, 
1135m, 759m, 699m. 1H-NMR for major isomer (CDCl3): 
13.03, 12.77 (2br. s, 2H, OH, NH); 8.27 (s, 1H, –N=CH–); 
7.34-7.20 (m, 6 arom. H); 7.12 (d, J = 7.8, 1 arom. H); 6.85 
(d, J = 8.4, 1 arom. H); 6.81-6.79 (m, 1 arom. H); 5.20 
(quint, J = 7.2, 1H); 5.14-5.10 (m, 1H, cHex); 4.14-4.09 
(m, 1H, cHex); 3.26-3.19 (m, 1H, cHex); 2.51 (s, 3H, Me); 
1.98-1.41 (m, 7H, cHex); 1.54 (d, J = 7.2, 3H, Me). 13C-
NMR for major isomer (CDCl3): 165.9 (s, –N=CH–); 161.0 
(s, (Ph)C-OH); 157.5, 157.4 (2s, CONH, C=S); 143.0, 
134.7, 118.9, 118.6 (4s, 2C(Ph), C(4), C(5)); 132.4, 131.7, 
128.6 (2C), 127.2, 126.3 (2C), 118.4, 117.0 (7d, 9CH(Ph)); 
65.1, 61.6, 49.1 (3d, 3CH); 34.6, 27.3, 25.3, 23.7 (4t, 
4CH2(cHex)); 21.9, 9.9 (2q, 2Me). ESI-HRMS: 485.1985 
(calcd. 485.1982 for C26H30N4NaO2S, [M+Na]+), 463.2166 
(calcd. 463.2162 for C26H31N4O2S, [M+1]+). [α]D25 = –
305.0 (c 1.00, CHCl3). 
4.7.7. Imidazole 16 
 Yield after CC (SiO2, AcOEt/CHCl3 1:1, isolated as 
more polar fraction, Rf = 0.44): 34 mg (8%). Yellow semi-
solid. IR (KBr): 3400m (br.), 2932s (br.), 2860m, 1653s, 
1630s, 1582s, 1494s, 1449m, 1278m, 1229m, 758m, 700m. 
1H NMR (CDCl3): 12.65 (s, 1H, OH); 7.91 (s, 1H, –
N=CH–); 7.40 (s, 1H, HC(2)); 7.33-7.28 (m, 2 arom. H); 
7.26-7.24 (m, 3 arom. H); 7.21-7.18 (m, 1 arom.H); 7.01 
(dd, J = 7.6, J = 1.6, 1 arom. H); 6.87 (d, J = 8.1, 1 arom. 
H); 6.76 (dt, J = 7.4, J = 1.1, 1 arom. H); 5.19 (quint, J = 
7.1, 1H); 4.06-4.01 (m, 1H, cHex); 3.36 (dt, J = 10.5, J = 
4.4, 1H, cHex); 2.51 (s, 3H, Me); 2.14-2.11 (m, 1H, cHex); 
2.02-1.75 (m, 6H, cHex); 1.54-1.49 (m, 1H, cHex); 1.51 (d, 
J = 7.1, 3H, Me). 13C NMR (CDCl3): 165.1 (s, –N=CH–); 
162.8 (s, (Ph)C-OH); 160.6 (s, CONH); 143.8, 132.6, 
130.7, 118.1 (4s, 2C(Ph), C(4), C(5)); 132.7, 131.5, 128.4 
(2C), 126.9, 126.1 (2C), 118.7, 117.0 (7d, 9CH(Ph)); 132.1 
(d, C(2)); 73.4, 58.7, 47.9 (3d, 3CH); 34.2, 32.8, 25.2, 23.9 
(4t, 4CH2(cHex)); 22.2, 9.6 (2q, 2Me). ESI-HRMS: 
453.2260 (calcd. 453.2261 for C26H30N4NaO2, [M+Na]+), 
431.2439 (calcd. 431.2442 for C26H31N4O2, [M+1]+). [α]D25 
= –174.8 (c 0.48, CHCl3) 
4.8. Deoxygenation of 10c with Raney-nickel 
 To the solution of 10c (101 mg, 0.26 mmol) in methanol 
(8.0 mL) a suspension of freshly prepared Raney-Ni in 
methanol was added in small portions at r.t., until the 
starting material was fully consumed (TLC monitoring). 
The crude mixture was filtered through Celite® pad, 
washed with MeOH, and the solvent was removed from the 
filtrate. The resulting residue was purified on preparative 
TLC plates (SiO2) using CHCl3/AcOEt mixture (2:1) to 
give 58 mg (61%) of 14 as a colorless solid. 
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